Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.
first published: May 15, 2012 04:33 pm
A collection of the most-viewed Moneycontrol videos.
Why This Tenant Says Bandra Is Better Than California | The Tenant
Nifty Clocks Triple-Digit Gains After RBI Rate Cut But Logs Losses For The Week| Closing Bell Live
LIVE: RBI Governor Sanjay Malhotra Delivers Key Monetary Policy Statement | Interest Rates & Outlook
Nifty’s Move Hinges On RBI Rate Decision; HUL, ITC Hotels In Focus| Opening Bell Live
